Precision Oncology Trials Still Enroll Mostly White Patients Despite Initiatives, Calls to DiversifyNEW YORK – When 65-year-old Agnes Ross was diagnosed with lung cancer in early 2019, she was told next to nothing about her diagnosis, let alone her cancer's molecular characteristics.Ross, a Black woman from Northern Virginia who formerly served in… Jul 06 20July 06, 2020Article at Precision Oncology News
Precision Oncology Drugmakers Are the IRA's Staunchest Adversaries—And They're Not Backing DownNEW YORK – A year after President Joe Biden signed the sweeping Inflation Reduction Act into law, giving the US Centers for Medicare & Medicaid Services the power to negotiate drug prices, the government payor and drugmakers have started negotiating… Oct 03 23October 03, 2023Article at ASCO Annual Meeting
Microbiome Therapeutics Find Their Footing in CancerNEW YORK — Jennifer Wargo's rationale for focusing her oncology career on the microbiome boils down to the numbers. "We're only 1 percent human, when it comes to our total genomic content," she said. "We're actually 99 percent microbial." Wargo, the… May 29 23May 29, 2023Article at Precision Oncology News
Pluvicto's Arrival in Prostate Cancer Brings Competition, Debate Over Imaging AgentsNEW YORK – It has only been one week since the US Food and Drug Administration approved Novartis' targeted radioligand therapy Pluvicto (177Lu-PSMA-617 or lutetium Lu 177 vipivotide tetraxetan), but oncologists, drugmakers, and nuclear medicine… Mar 30 22March 30, 2022Article at Precision Oncology News
Patients Are Dying Waiting for Pluvicto, but Novartis Can't Make More Pending Facility ApprovalNEW YORK – On Wednesday morning, Young Whang, an oncologist at the University of North Carolina at Chapel Hill, made the difficult decision to switch one of his patients with advanced prostate cancer to a different systemic therapy, despite the fact… Mar 02 23March 02, 2023Article at Precision Oncology News
Drugmakers Face Uncertain Regulatory Pathways in Bringing Novel Cell Therapies to MarketNEW YORK – Drugmakers developing autologous cancer cell therapies are struggling to navigate uncertain regulatory requirements and are asking agencies to provide concrete guidance on approval criteria. Autologous cell therapies are n-of-1 treatments… Oct 23 21October 23, 2021Article at Precision Oncology News
Oncologists, Patients Still Face Unpredictable Payor Coverage for Broad Tissue NGS Panels NEW YORK – It's been three years since her advanced lung cancer diagnosis, and still 54-year-old Michelle Hills can't wrap her head around the fact that her health insurance, a Cigna plan, didn't cover the next-generation sequencing biomarker test… May 16 21May 16, 2021Article at Precision Oncology News
Autologous TIL Therapy Benefits Rare, Difficult-to-Treat Melanoma Subset, ESMO Data ShowNEW YORK – Iovance Biotherapeutics' autologous tumor-infiltrating lymphocyte (TIL) therapy led to what researchers at the European Society for Medical Oncology (ESMO) Congress on Saturday considered meaningful and encouraging responses in a small… Oct 21 23October 21, 2023Article at Precision Oncology News
Oncologists Look to FDA as New Publications Poke Holes in TMB-High Keytruda Approval NEW YORK – Amid mounting data suggesting that certain advanced solid tumors don't benefit from pembrolizumab (Merck's Keytruda) despite having high tumor mutational burden (TMB), more and more oncologists are starting to question whether the US… Mar 24 21March 24, 2021Article at Precision Oncology News
Pluvicto Delays Progression in Earlier mCRPC, but Crossover Muddies Overall Survival AnalysisNEW YORK – Novartis' targeted radiopharmaceutical Pluvicto (lutetium vipivotide tetraxetan) more than doubled the median progression-free survival for patients with metastatic castration-resistant prostate cancer who hadn't received chemo before,… Oct 23 23October 23, 2023Article at Precision Oncology News
In Small Prostate Cancer Trial, UCSF Researchers Present a Case for Pluvicto-Keytruda ComboNEW YORK – Researchers at the University of California, San Francisco have shown in a study published in Lancet Oncology this week that a single dose of Novartis' radiopharmaceutical Pluvicto (lutetium vipivotide tetraxetan) followed by Merck's… Nov 02 23November 02, 2023Article at Precision Oncology News
Outcomes4Me Partnering With Commercial Labs, Pharma to Expand Precision Oncology AccessNEW YORK – Outcomes4Me is optimistic that a newly inked deal with Labcorp and partnerships with pharmaceutical companies will help it improve cancer patients' access to biomarker testing and precision treatment. The Boston-based company, founded in… Sep 25 23September 25, 2023Article at ASCO Annual Meeting
Novartis Focused on Radiopharmaceutical Expansion After Pluvicto, Lutathera Sales Both Grow in Q3NEW YORK – Sales of Novartis' Pluvicto (lutetium vipivotide tetraxetan) soared 220 percent during the third quarter, and the firm is pointing to a data readout as a harbinger of continued commercial expansion for the new radiopharmaceutical. For the… Oct 23 23October 23, 2023Article at Precision Oncology News
Princeton University Spinout KayoThera Marching Toward Clinic With Retinoid Pathway InhibitorNEW YORK – Earlier this week, Princeton University spinout KayoThera announced plans to advance a lead candidate, KAYO-1609, toward first-in-human clinical trials in difficult-to-treat, genetically defined cancers including those with alterations in… Sep 20 23September 20, 2023Article at ASCO Annual Meeting
Genomic Medicine 'Sales Pitch' Doesn't Sit Well With Those Left Out of Research in UK StudyNEW YORK – People who have traditionally been excluded from genomics studies and have difficulties accessing medical advances were skeptical when researchers touted the benefits of precision medicine, according to a report published Thursday in Human… Aug 30 23August 30, 2023Article at Precision Oncology News
Agendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrintNEW YORK – Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes downstaged following neoadjuvant chemotherapy has the company optimistic about a… Oct 10 23October 10, 2023Article at Precision Oncology News
Pre-Surgery Immunotherapy, This Time With an Anti-LAG3/PD-1 Duo, Wows Again at ESMONEW YORK – All 19 patients with non-metastatic DNA mismatch repair-deficient (dMMR) colorectal cancer responded to neoadjuvant treatment with Bristol Myers Squibb's Opdualag (nivolumab plus relatlimab) in the Phase II NICHE-3 trial, researchers… Oct 21 23October 21, 2023Article at Precision Oncology News
Gilead Sciences' Trodelvy Gains Ground With 64 Percent Revenue Jump in Q2NEW YORK – Gilead Sciences has big plans for its TROP2-directed antibody-drug conjugate Trodelvy (sacituzumab govitecan), which ranked among its top-selling precision oncology drugs in Q2 2023 with 64 percent sales growth year over year, the company… Aug 03 23August 03, 2023Article at Precision Oncology News
Impilo Therapeutics Bets on Stroma-Penetrating Platform to Bring Nucleic Acid Therapies to CancerNEW YORK – Nucleic acid-based therapies haven't had much success treating cancer, but newly launched Impilo Therapeutics wants to change that. San Diego-based Impilo, which officially launched this week, aims to develop nucleic acid-based therapies… Aug 16 23August 16, 2023Article at Precision Oncology News
LUNGevity, Moffitt Cancer Center to Study Precision Oncology Disparities in Black NSCLC PatientsNEW YORK – LUNGevity and the Moffitt Cancer Center are making a push to better quantify and improve biomarker testing access for Black patients with non-small cell lung cancer. Within the Joining Us Together to Improve Lung Cancer Equity (JUSTICE)… Aug 08 23August 08, 2023Article at Precision Oncology News
Breast Cancer Study Informs Affibody, GE HealthCare's Development Path for HER2 RadiopharmaceuticalNEW YORK – Affibody and GE HealthCare's development plans for 68Ga-ABY-025 are starting to take shape after the diagnostic radiopharmaceutical showed it could predict which breast cancer patients benefit from HER2-targeted treatment in a Phase II… Oct 17 23October 17, 2023Article at Precision Oncology News
